CURRICULUM VITAE

Date of Revision:	July 24, 2020
Name:	Scott Huntington, MD, MPH, MSc
School:	Yale School of Medicine

Education:

MD, Mount Sinai School of Medicine 2009
MPH, Mount Sinai School of Medicine 2009
MSc, University of Pennsylvania Health Policy 2015

Career/Academic Appointments:

2009 - 2012	Residency, Internal Medicine, Vanderbilt University, Nashville, TN
2012 - 2015	Fellowship, Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
2015 - present	Assistant Professor, Hematology, Yale School of Medicine, New Haven, CT

Administrative Positions:

2019 - present	Medical Director, Hematology Outpatient Program, Smilow Cancer Hospital, New Haven, CT

Board Certification:

AB of Internal Medicine, Internal Medicine, 08-2012

Professional Honors & Recognition:

International/National/Regional

2019	40 under 40 in Cancer: Rising Starts and Emerging Leaders
2016	Patient Access Network and American Journal of Managed Care, First place research prize
2014	American Society of Clinical Oncology, Conquer Cancer Foundation of ASCO Merit Award

Other

2014	Leonard Davis Institute, University of Pennsylvania, Armstrong Founders Award

Grants/Clinical Trials History:

Current Grants

Agency:	Deluca Foundation

I.D.#:	Deluca Pilot
Title:	Evaluating variation of patient characteristics at time of treatment initiation for patients with chronic lymphocytic leukemia treated in the US community setting
Role:	Principal Investigator
Percent effort:	N/A
Direct costs per year:	$50,000.00
Total costs for project period:	$50,000.00
Project period:	1/1/2020 - 12/31/2020

Current Clinical Trials

Agency:	Cartesian Therapeutics, Inc.
I.D.#:	HIC# 2000025977
Title:	Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	1/30/2020

Agency:	Novartis Pharmaceuticals
I.D.#:	HIC# 2000025634
Title:	Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/14/2019

Agency:	National Cancer Institute (NCI)
I.D.#:	HIC# 2000025056
Title:	A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
P.I.:	Elan Gorshein
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project	

period:	N/A
Project period:	7/1/2019
Agency:	Daiichi Sankyo
I.D.#:	HIC# 2000024688
Title:	A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	4/9/2019
Agency:	miRagen Therapeutics, Inc.
I.D.#:	HIC# 2000023886
Title:	A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	3/15/2019
Agency:	Agios Pharmaceuticals
I.D.#:	HIC# 2000024525
Title:	A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	2/7/2019
Agency:	Oncternal Therapeutics, Inc.
I.D.#:	HIC# 2000024021
Title:	A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
P.I.:	Iris Isufi
Role:	Sub-Investigator

Percent effort:	N/A
Total costs for project period:	N/A
Project period:	2/6/2019

Agency:	Unum Therapeutics
I.D.#:	HIC# 2000024211
Title:	Long-Term Follow-Up Study of Clinical Study Subjects Treated with An Autologous T Cell Product Expressing An Antibody-Coupled T-Cell Receptor (ACTR)
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	1/2/2019

Agency:	AbbVie Inc.
I.D.#:	HIC# 2000022803
Title:	A Single Arm, Open-Label Pilot Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) Stage IB to IV
P.I.:	Michael Girardi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	10/11/2018

Agency:	University of Chicago
I.D.#:	HIC# 2000022076
Title:	Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	4/23/2018

Agency:	Acerta Pharma, LLC
I.D.#:	HIC# 2000021105
Title:	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With

	Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	10/22/2017

Agency:	Zhejiang DTRM Biopharma Co. Ltd.
I.D.#:	HIC# 2000021088
Title:	A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	9/29/2017

Agency:	Celgene Corporation
I.D.#:	HIC# 2000020507
Title:	A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/2/2017

Agency:	Eisai Pharmaceuticals
I.D.#:	HIC# 2000020362
Title:	A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	6/15/2017

Agency:	Celgene Corporation
I.D.#:	HIC# 1605017695

Title:	A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
P.I.:	David Witt
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/31/2016

Agency:	National Cancer Institute (NCI)
I.D.#:	HIC# 1609018346
Title:	A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/31/2016

Agency:	Kura Oncology, Inc.
I.D.#:	HIC# 1606017905
Title:	An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/3/2016

Agency:	TG Therapeutics, Inc.
I.D.#:	HIC# 1604017652
Title:	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	7/26/2016

Agency:	TG Therapeutics, Inc.
I.D.#:	HIC# 1604017653
Title:	A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	7/26/2016

Agency:	Vanderbilt-Ingram Cancer Center
I.D.#:	HIC# 1603017437
Title:	Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
P.I.:	Nikolai Podoltsev
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	$5,029.00
Project period:	5/20/2016

Agency:	F. Hoffman-La Roche Ltd
I.D.#:	HIC# 1510016732
Title:	A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	3/4/2016

Agency:	Celgene Corporation
I.D.#:	HIC# 1509016487
Title:	A Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A

Total costs for project period:	N/A
Project period:	12/23/2015

Agency:	Astex Pharmaceuticals, Inc.
I.D.#:	HIC# 1505015798
Title:	Phase I-II Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/19/2015

Agency:	Children's Oncology Group (COG)
I.D.#:	HIC# 1504015712
Title:	A Phase I/II Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma
P.I.:	Nina Kadan-Lottick
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	5/19/2015

Agency:	Eastern Cooperative Oncology Group (ECOG)
I.D.#:	HIC# 1407014256
Title:	Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	11/14/2014

Agency:	Alliance for Clinical Trials in Oncology
I.D.#:	HIC# 1404013770
Title:	Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Role:	Principal Investigator

Percent effort:	N/A
Total costs for project period:	N/A
Project period:	6/26/2014

Agency:	Celgene Corporation
I.D.#:	HIC# 1312013122
Title:	Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	5/7/2014

Agency:	National Institute of Diabetes and Digestive & Kidney Diseases (NIDDKD)
I.D.#:	HIC# 1401013259
Title:	Specimen Repository for Hematologic Diseases
P.I.:	Stephanie Halene
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	2/21/2014

Agency:	Janssen Pharmaceuticals
I.D.#:	HIC# 1306012216
Title:	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/15/2013

Agency:	Southwest Oncology Group (SWOG)
I.D.#:	HIC# 1207010543
Title:	S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
P.I.:	Iris Isufi

Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/28/2012

Past Grants

Agency:	Luekemia and Lymphoma Society
I.D.#:	LLS Pilot
Title:	Provider Characteristics and Receipt of the Newest Myeloma Agents
P.I.:	Davidoff, Amy
Role:	Collaborator
Percent effort:	2%
Direct costs per year:	$7,500.00
Total costs for project period:	$75,000.00
Project period:	7/1/2019 - 6/30/2020

Agency:	NCATS/NIH
I.D.#:	KL2 TR001862
Title:	Curbing unnecessary diagnostic imaging: Barriers to adopting non-imaging based routine surveillance for patients with lymphoma
P.I.:	Gross, Cary
Role:	Principal Investigator (Institutional holder Eugene Shapiro)
Percent effort:	N/A
Direct costs per year:	$120,000.00
Total costs for project period:	$240,000.00
Project period:	12/31/2016 - 12/31/2018

Agency:	Yale Cancer Center
I.D.#:	YCC Pilot
Title:	Real-world rituximab use in older adults with lymphoma
Role:	Principal Investigator
Percent effort:	N/A
Direct costs per year:	$50,000.00
Total costs for project period:	$50,000.00
Project period:	4/1/2016 - 12/31/2017

Past Clinical Trials

Agency:	Celgene Corporation
I.D.#:	HIC# 1603017334

Title:	A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
P.I.:	Amer Zeidan
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	$43,552.00
Project period:	5/17/2016 - 2/21/2020

Agency:	Immune Design Corp.
I.D.#:	HIC# 1507016207
Title:	A Phase I/II Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	12/2/2015 - 1/17/2020

Agency:	Yale Cancer Center
I.D.#:	HIC# 2000021483
Title:	Pilot Phase 2 Study of Intratumoral G100 in Patients With Cutaneous T Cell Lymphoma
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/20/2018 - 12/13/2019

Agency:	Celgene Corporation
I.D.#:	HIC# 1508016291REG
Title:	Analyzing the outcome of patients treated at Yale cancer center for a hematological disease : the Yale Hematology Registry
P.I.:	Thomas Prebet
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	$40,638.00
Project period:	10/7/2015 - 11/25/2019

Agency:	Cancer Immunotherapy Trials Network
I.D.#:	HIC# 1410014850
Title:	CITN-10: A Phase 2 Study of MK-3475 for the treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	12/8/2014 - 11/15/2019

Agency:	NO FUNDING
I.D.#:	HIC# 2000026305EXEMPT
Title:	Social Needs in Patients with Cancer
P.I.:	Cary Gross
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	9/18/2019 - 9/18/2019

Agency:	Boston Biomedical, Inc.
I.D.#:	HIC# 2000021051
Title:	A Phase 1 Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
P.I.:	Thomas Prebet
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/18/2017 - 8/14/2019

Agency:	Debiopharm International S.A.
I.D.#:	HIC# 1601017103
Title:	A Phase II Study to Evaluate the Efficacy and Tolerability of IMGN529 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	10/7/2016 - 7/5/2019

Agency:	Celgene Corporation
I.D.#:	HIC# 1604017647
Title:	A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes
P.I.:	Thomas Prebet
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	$26,714.00
Project period:	7/14/2016 - 7/2/2019

Agency:	Kyowa Hakko Kirin Co., Ltd.
I.D.#:	HIC# 1212011230
Title:	Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	3/6/2013 - 3/14/2019

Agency:	Affimed GmbH
I.D.#:	HIC# 2000020111
Title:	A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)
P.I.:	Gottfried von Keudell
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	3/1/2017 - 1/11/2019

Agency:	NO FUNDING
I.D.#:	HIC# 2000021403MRR
Title:	Outcomes of Patients with Relapsed/Refractory Hodgkin Lymphoma Treated with PD-1 Inhibitors Outside of Clinical Trials
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Project period:	8/25/2017 - 10/16/2018
Agency:	NO FUNDING
I.D.#:	HIC# 2000021402MRR
Title:	Clinical outcomes following ibrutinib and venetoclax based therapy in chronic lymphocytic leukemia: A multi-center retrospective analysis
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	9/12/2017 - 9/14/2018
Agency:	Seattle Genetics, Inc.
I.D.#:	HIC# 2000020361
Title:	A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	4/5/2017 - 9/13/2018
Agency:	Yale University
I.D.#:	HIC# 1610018579MRR
Title:	Outcomes and patterns of treatment of patients with Primary Mediastinal B-cell Lymphoma (PMBCL) before and after the advent of dose-adjusted EPOCH-R chemotherapy as a first line treatment option (MEDICAL RECORD REVIEW)
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	12/21/2016 - 4/16/2018
Agency:	Karyopharm Therapeutics, Inc.
I.D.#:	HIC# 1411014855
Title:	Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)
P.I.:	Steven Gore
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project	

period:	$15,580.00
Project period:	5/15/2015 - 3/28/2018
Agency:	Yale Cancer Center
I.D.#:	HIC# 1507016111
Title:	Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2)
P.I.:	Madhav Dhodapkar
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	9/8/2015 - 2/22/2018
Agency:	Innate Pharma SA
I.D.#:	HIC# 2000020765
Title:	Open Label 1b/2a Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
P.I.:	Gottfried von Keudell
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	9/2/2017 - 12/6/2017
Agency:	Boehringer Ingelheim Pharmaceuticals, Inc.
I.D.#:	HIC# 1311013040
Title:	An open label, Phase I, dose escalation trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of volasertib in combination with decitabine in patients ≥ 65 years with acute myeloid leukemia
P.I.:	Nikolai Podoltsev
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	$41,199.00
Project period:	4/24/2014 - 5/3/2017
Agency:	Merck Sharp & Dohme
I.D.#:	HIC# 1604017583
Title:	A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

P.I.:	Gottfried von Keudell
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	7/26/2016 - 3/3/2017

Pending Clinical Trials

Agency:	NO FUNDING
I.D.#:	HIC# 2000027855MRR
Title:	Examining COVID19 course and outcomes in patients previously diagnosed with chronic lymphocytic leukemia (CLL)
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	4/9/2020

Agency:	NO FUNDING
I.D.#:	HIC# 2000027401MRR
Title:	Real-World Outcomes and Practice Variation in Central Nervous System Prophylaxis During Frontline Therapy in Aggressive B-cell Non-Hodgkin s Lymphoma
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	2/27/2020

Agency:	University of Chicago
I.D.#:	HIC# 2000022522
Title:	A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the combination of Pembrolizumab with TGR-1202 in patients with relapsed/refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	2/8/2020

Agency:	Celgene Corporation
I.D.#:	HIC# 2000025979

Title:	A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
P.I.:	Noffar Bar
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	1/17/2020

Agency:	NO FUNDING
I.D.#:	HIC# 2000026933EXEMPT
Title:	Understanding the causes of early mortality in newly diagnosed multiple myeloma: Retrospective analysis of patients from the Flatiron Myeloma Cohort
P.I.:	Natalia Neparidze
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	1/17/2020

Agency:	Southwest Oncology Group (SWOG)
I.D.#:	HIC# 2000026357
Title:	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	8/27/2019

Agency:	Eastern Cooperative Oncology Group (ECOG)
I.D.#:	HIC# 2000025050
Title:	A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	2/27/2019

Agency:	Memorial Sloan-Kettering Cancer Center

I.D.#:	HIC# 2000023030
Title:	A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	10/3/2018

Agency:	Eastern Cooperative Oncology Group (ECOG)
I.D.#:	HIC# 2000023593
Title:	A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	7/3/2018

Agency:	Curis, Inc
I.D.#:	HIC# 2000022049
Title:	An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	4/17/2018

Agency:	Bristol-Myers Squibb Research and Development
I.D.#:	HIC# 2000021039
Title:	Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
P.I.:	Nina Kadan-Lottick

Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	3/22/2018

Agency:	Southwest Oncology Group (SWOG)
I.D.#:	HIC# 2000022077
Title:	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
P.I.:	Syed Bilgrami
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	1/10/2018

Agency:	Alliance for Clinical Trials in Oncology
I.D.#:	HIC# 2000020994
Title:	A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	4/6/2017

Agency:	National Cancer Institute (NCI)
I.D.#:	HIC# 1608018198
Title:	A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	9/28/2016

Agency:	Genentech, Inc.
I.D.#:	HIC# 1509016491
Title:	An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed

	or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	2/10/2016

Agency:	miRagen Therapeutics, Inc.
I.D.#:	HIC# 1507016232
Title:	A Phase I Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A
Project period:	11/2/2015

Agency:	Dana-Farber Cancer Institute
I.D.#:	HIC# 2000026258
Title:	A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Agency:	Seattle Genetics, Inc.
I.D.#:	HIC# 2000026695
Title:	A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Adults Age 60 and Above
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Agency:	PrECOG, LLC

I.D.#:	HIC# 2000027279
Title:	Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
P.I.:	Shalin Kothari
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Agency:	Portola Pharmaceuticals, Inc.
I.D.#:	HIC# 2000027358
Title:	CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Agency:	Loxo Oncology, Inc.
I.D.#:	HIC# 2000027406
Title:	A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Agency:	City of Hope Medical Center
I.D.#:	HIC# 2000027634
Title:	A phase II trial of response-adapted second-line therapy for Hodgkin lymphoma using anti-PD-1 antibody nivolumab ± ICE chemotherapy as a bridge to autologous hematopoietic cell transplant (NICE Trial)
P.I.:	Iris Isufi
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Agency:	Seattle Genetics, Inc.
I.D.#:	HIC# 2000027638
Title:	A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies

P.I.:	Francine Foss
Role:	Sub-Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Agency:	Epizyme, Inc.
I.D.#:	HIC# 2000028637
Title:	A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Role:	Principal Investigator
Percent effort:	N/A
Total costs for project period:	N/A

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:

International/National

2019: American Society of Hematology, Orlando, FL. "Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States"

Professional Service:

Advisory Boards

2018 - present Board Member, Expert Work Group: Development, Reevaluation, and Implementation of Outpatient Outcome and Efficiency Measures, Mathematica Policy Research

Professional Service for Professional Organizations

National Comprehensive Cancer Network

2018 - present Committee Member, National Comprehensive Cancer Network, Chemotherapy Order Template Committee Member

Yale University Service

Hospital Boards & Committees

2016 - present Vice Chair, Oncology Pharmacy and Therapeutics Subcommittee

Bibliography:

Peer-Reviewed Original Research

1. **Huntington SF**, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 2012, 53:1461-8.
2. Evans AG, Rothberg PG, Burack WR, **Huntington SF**, Porter DL, Friedberg JW, Liesveld JL. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. British Journal Of Haematology 2015, 171:205-209.
3. **Huntington SF**, Nasta SD, Schuster SJ, Doshi JA, Svoboda J. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 2015, 56:2579-84.
4. **Huntington SF**, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33:1467-74.
5. **Huntington SF**, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. The Lancet. Haematology 2015, 2:e408-16.
6. Doshi JA, Li P, Huo H, Pettit AR, Kumar R, Weiss BM, **Huntington SF**. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. The American Journal Of Managed Care 2016, 22:s78-86.
7. Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, **Huntington SF**, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175:829-840.
8. **Huntington SF**, Davidoff AJ. High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34:4307-4309.
9. **Huntington SF**. Cancer-related financial toxicity: beyond the realm of drug pricing and out-of-pocket costs. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2016, 27:2143-2145.
10. Zeidan AM, Long JB, Wang R, Hu X, Yu JB, **Huntington SF**, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PloS One 2017, 12:e0184747.
11. Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, **Huntington SF**, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35:3417-3424.
12. Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, **Huntington SF**. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123:3763-3771.
13. Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, **Huntington SF**, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. Cancer 2017, 123:3754-3762.

14. Zeidan AM, Wang R, Gross CP, Gore SD, **Huntington SF**, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia & Lymphoma 2017, 58:982-985.
15. Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, **Huntington SF**, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. The Prostate 2017, 77:437-445.
16. Shah NN, Szabo A, **Huntington SF**, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xaiver AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. British Journal Of Haematology 2018, 180:534-544.
17. Zeidan AM, Stahl M, Hu X, Wang R, **Huntington SF**, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2018, 131:818-821.
18. Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, **Huntington SF**. The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. American Journal Of Hematology 2018, 93:874-881.
19. Mato A, Jahnke J, Li P, Mehra M, Ladage VP, Mahler M, **Huntington S**, Doshi JA. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. Haematologica 2018, 103:e462-e465.
20. Zeidan AM, Stahl M, DeVeaux M, Giri S, **Huntington S**, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer Journal 2018, 8:55.
21. **Huntington S**, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leukemia & Lymphoma 2018, 59:2880-2887.
22. **Huntington SF**, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 2018, 124:4211-4220.
23. **Huntington SF**, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, JCO1800122.
24. Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, **Huntington SF**, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2:2681-2690.
25. Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, **Huntington SF**, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. The Oncologist 2019, 24:955-962.
26. Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, **Huntington SF**, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential

Thrombocythemia. Journal Of The National Comprehensive Cancer Network : JNCCN 2019, 17:211-219.

27. Giri S, **Huntington SF**. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer. JAMA Oncology 2019, 5:1066.
28. Bewersdorf JP, Shallis R, Wang R, **Huntington S**, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12:641-650.
29. Zeidan AM, Zhu W, Stahl M, Wang R, **Huntington SF**, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60:3181-3187.
30. **Huntington SF**, Zhu W, Hoag JR, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum 2019, 3:pkz030.
31. Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, **Huntington SF**. Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125:4084-4095.
32. Zeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, **Huntington SF**, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. Cancer 2019, 125:4241-4251.
33. **Huntington SF**, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network : JNCCN 2019, 17:1194-1202.
34. **Huntington SF**. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology / The Education Program Of The American Society Of Hematology. American Society Of Hematology. Education Program 2019, 2019:252-259.
35. Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, **Huntington SF**, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2020, 61:397-408.
36. Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, **Huntington SF**, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2020, 61:1178-1187.
37. Henckel C, Revette A, **Huntington SF**, Tulsky JA, Abel GA, Odejide OO. Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers. Journal Of Pain And Symptom Management 2020, 59:1195-1203.e4.
38. Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, **Huntington SF**, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4:1615-1623.
39. Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, **Huntington SF**, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4:2192-2201.

40. Giri S, **Huntington SF**, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4:2245-2253.
41. Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, **Huntington SP**, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020.
42. Patel K, Isufi I, Kothari S, Davidoff AJ, Gross CP, **Huntington SF**. Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia. Blood 2020.

Invited Editorials and Commentaries

43. **Huntington SF**, Gross CP. Negative Studies in Cancer Research: Why the Negativity? JAMA Oncology 2016, 2:865-6.
44. **Huntington SF**, Davidoff AJ, Gross CP. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38:351-358.

Case Reports, Technical Notes, Letters

45. **Huntington SF**, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Reply to H.J.A. Adams et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37:853-854.